Compare GENB & ATEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GENB | ATEC |
|---|---|---|
| Founded | 2018 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | N/A | 2006 |
| Metric | GENB | ATEC |
|---|---|---|
| Price | $12.25 | $11.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 709.7K | ★ 2.3M |
| Earning Date | 05-03-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $101,739,000.00 |
| Revenue This Year | N/A | $18.97 |
| Revenue Next Year | N/A | $16.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.00 | $8.82 |
| 52 Week High | $13.95 | $23.29 |
| Indicator | GENB | ATEC |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 33.98 |
| Support Level | $11.26 | $10.21 |
| Resistance Level | $13.70 | $12.97 |
| Average True Range (ATR) | 0.96 | 0.53 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 39.81 | 9.03 |
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.